The FDA approval of the first oral GLP-1 for weight loss in December 2025-Novo Nordisk's once-daily semaglutide pill-represents a watershed moment for the category [3]
Minimize heavy makeup application for the first 24 hours
GLP-1 is an incretin hormone that stimulates insulin secretion in a glucose-dependent manner, reducing hypoglycaemia risk The hormone slows gastric emptying and suppresses appetite through receptors in the pancreas, brain, and gastrointestinal tract GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) are MHRA-approved for type 2 diabetes and weight management Common side effects include nausea, vomiting, and diarrhoea due to delayed gastric emptying and altered gut motility Patients should seek urgent medical attention for severe abdominal pain with persistent vomiting, as this may indicate pancreatitis GLP-1 medications do not directly impair digestive enzyme production, and routine enzyme supplementation is not clinically indicated Table of Contents What Does GLP-1 Stand For
Two initial testing sessions, seven days apart, lasting 90 minutes were completed following randomization
We are currently exploring cationic or neutral water solubilizing groups to replace the carboxylic acids in RT to achieve higher temporal resolution while maintaining homogeneous cellular distribution, which will be reported in the due course